Selvita Will Present New Data From Its PIM/FLT3 And MNK1/2 Oncology Programs During American Association for Cancer Research Annual Meeting 2014
3/11/2014 10:21:30 AM
Krakow, Poland, March 11, 2014 / B3C newswire / –Selvita, the largest independent drug discovery company in Central and Eastern Europe, will present new data at poster sessions at AACR Annual Meeting 2014, which will take place on April 5 - 9, 2014 at San Diego Convention Center, San Diego, California, USA.
Selvita will present two posters:
1. The poster entitled "Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancer" will be presented at the session on Sunday, April 6th, 2014, 1:00 PM - 5:00 PM, Hall A-E, Poster Section 31, poster board number 28.
2. The poster entitled "Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies" will be presented at the session on Monday, April 7th, 2014, 8:00 AM - 12:00 PM, Hall A-E, Poster Section 31, poster board number 22.
“We are extremely pleased to present the research progress from our advanced oncology programs at the prestigious AACR Annual Meeting 2014” – said Dr. Krzysztof Brzozka, Selvita’s Chief Scientific Officer. “In SEL201 Project we are studying the potential of targeting novel kinase targets in oncology, such as MNK1/2 kinases which are linked in the literature to modulation of translation in various malignancies. Selvita has developed the most selective series of MNK1/2 inhibitors reported so far and is currently exploring therapeutic potential of this group of compounds in solid tumors, especially in combination with other agents targeting translation such as PI3K/mTOR pathway inhibitors.
Within SEL24 project Selvita is exploring the potential of targeting two critical kinases shown to be crucial for development of hematological malignances and pursued by our competitors using target-selective inhibitors. We have developed the first in class molecule targeting selectively mutated forms of FLT3 and downstream effectors of FLT3 signaling, namely the family of PIM kinases. Our dual-activity, clinical candidate molecule, SEL24-B489 shows superior activity on a panel of AML models, both in vitro and in vivo in comparison to single-target inhibitors, excellent bioavailability and promising initial toxicology profile. On top of these data, observed synergism with cytarabine further increases the chances of success of our drug in clinical trials which we plan to commence in 2015.”
Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 190 people, including over 62 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014. The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors, SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Other innovative projects currently in development include SEL141, an early stage discovery program of a series of DYRK1A kinase inhibitors with therapeutic potential in the treatment of tauopathies including Alzheimer's disease and Down syndrome, SEL201 – novel small molecule MNK1/2 inhibitors in oncology, SEL300 – novel small molecules targeting cancer metabolism and SEL212, NALP3 inflammasome modulators for the treatment of autoinflammatory and autoimmune disorders. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the NewConnect market of the Warsaw Stock Exchange in Poland (SLV).
+48 668 111 456
Help employers find you! Check out all the jobs and post your resume.
comments powered by